Jason G Powell (Jason Powell)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 6

Top Topics

Respiratory Syndrome Coronavirus

Drug Administration

Top Venues

The Annals of pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Christie Monahan, Lindsey McCoy, Jason G Powell, John G Gums
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia. The Annals of pharmacotherapy 56 (9) (2022)
Jason G Powell, Christopher R Piszczatoski
Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon. The Annals of pharmacotherapy 56 (9) (2022)
Jason G Powell, Christopher R Piszczatoski, Eric Rubido
Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema. The Annals of pharmacotherapy (2021)
Christopher R Piszczatoski, Jason G Powell
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. The Annals of pharmacotherapy 54 (8) (2020)
Jason G Powell, Chris Piszczatoski, Scott Garland
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea. The Annals of pharmacotherapy 54 (10) (2020)
Jason G Powell, Scott Garland, Kayla Preston, Chris Piszczatoski
Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. The Annals of pharmacotherapy 54 (2) (2019)